Corrected: Drug delivery CDMO earmarks $365M to expand injectable device capacity

Anna Brown

News Reporter

PCI Pharma Services is pouring $365 million to expand its US and Irish footprint for commercial and clinical packaging of drug-device products to meet evolving …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Corrected: Drug delivery CDMO earmarks $365M to expand injectable device capacity

Anna Brown

News Reporter

Sign up to read this article for free.

Pfizer’s prostate cancer data leak shows promising results in early-stage study

Novartis returns for its anticoagulant in up to $3.1B buy of Blackstone’s Anthos

Judge halts some NIH cuts after 22 states sue

Vertex operations chief Stuart Arbuckle to retire

Merck KGaA confirms interest in acquiring cancer biotech SpringWorks

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

Cor­rect­ed: Drug de­liv­ery CD­MO ear­marks $365M to ex­pand in­jectable de­vice ca­pac­i­ty

Anna Brown

News Reporter

Sign up to read this article for free.

Pfiz­er’s prostate can­cer da­ta leak shows promis­ing re­sults in ear­ly-stage study

No­var­tis re­turns for its an­ti­co­ag­u­lant in up to $3.1B buy of Black­stone’s An­thos

Judge halts some NIH cuts af­ter 22 states sue

Ver­tex op­er­a­tions chief Stu­art Ar­buck­le to re­tire

Mer­ck KGaA con­firms in­ter­est in ac­quir­ing can­cer biotech Spring­Works

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

Corrected: Drug delivery CDMO earmarks $365M to expand injectable device capacity

Pfizer’s prostate cancer data leak shows promising results in early-stage study

Novartis returns for its anticoagulant in up to $3.1B buy of Blackstone’s Anthos

Judge halts some NIH cuts after 22 states sue

Vertex operations chief Stuart Arbuckle to retire

Merck KGaA confirms interest in acquiring cancer biotech SpringWorks

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers